• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Recent Advances in the Application of 3-Amino-2-bromo-6-fluorophenol (CAS: 1805504-59-9) in Chemical Biology and Pharmaceutical Research

3-Amino-2-bromo-6-fluorophenol (CAS: 1805504-59-9) is a halogenated aromatic compound that has recently gained attention in chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery and development. This compound serves as a versatile intermediate in the synthesis of various biologically active molecules, particularly in the construction of kinase inhibitors and other small-molecule therapeutics. Recent studies have explored its utility in medicinal chemistry, highlighting its role as a key building block for targeted therapies.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 3-Amino-2-bromo-6-fluorophenol as a precursor in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The research team successfully incorporated this compound into a series of potent inhibitors showing improved selectivity and pharmacokinetic properties compared to existing therapies. The presence of both bromine and fluorine atoms in the structure allowed for precise modifications of the inhibitor's binding affinity, underscoring the compound's value in structure-activity relationship (SAR) studies.

In the field of radiopharmaceuticals, recent work has investigated the potential of 3-Amino-2-bromo-6-fluorophenol as a labeling precursor for positron emission tomography (PET) tracers. The compound's fluorine atom provides an ideal site for 18F-radiolabeling, while the amino group offers additional functionalization possibilities. A 2024 study in Nuclear Medicine and Biology reported successful radiolabeling yields exceeding 85%, suggesting promising applications in diagnostic imaging for various diseases.

The compound's mechanism of action in biological systems has been further elucidated through recent computational chemistry studies. Molecular docking simulations published in Bioorganic & Medicinal Chemistry Letters (2024) revealed that derivatives of 3-Amino-2-bromo-6-fluorophenol exhibit favorable interactions with several cancer-related protein targets. These findings support the compound's potential as a scaffold for developing new anticancer agents with improved target specificity.

From a synthetic chemistry perspective, recent advances have been made in optimizing the production of 3-Amino-2-bromo-6-fluorophenol. A 2023 patent application disclosed an improved synthetic route that increases yield while reducing hazardous byproducts. This development is particularly significant for scaling up production to meet the growing demand in pharmaceutical research and development.

Looking forward, researchers anticipate expanding applications of 3-Amino-2-bromo-6-fluorophenol in fragment-based drug discovery and covalent inhibitor design. The compound's unique combination of functional groups makes it particularly valuable for exploring new chemical space in drug development. Ongoing clinical trials involving molecules derived from this scaffold are expected to report results in the coming year, potentially validating its therapeutic potential in various disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)